Offer was a 29% increase to Kite's closing price on Friday....
I've read that this is a new class of drug but to be used in the field on oncology and will be used with other immunotherapies.
Hoping that this is a good sign for Cavatak and VLA and there is still a huge appetite for cancer therapies!